We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Value of Serum CHI3L1 in Hepatocellular Carcinoma Explored

By LabMedica International staff writers
Posted on 02 Feb 2022
Print article
Image: The Proprium Fibro-CHI Diagnostic ELISA Kit for the quantification of Chitinase 3-Like 1 (CHI3L1) in serum and plasma (Photo courtesy of Proprium Biotech Company Limited)
Image: The Proprium Fibro-CHI Diagnostic ELISA Kit for the quantification of Chitinase 3-Like 1 (CHI3L1) in serum and plasma (Photo courtesy of Proprium Biotech Company Limited)
Primary liver cancer is the sixth diagnosed cancer and the fourth cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC) is the major pathological category and comprises a 75%–85% incidence of primary liver cancer cases.

Chitinase 3-like protein 1 (CHI3L1) belongs to the family 18-glycosyl hydrolase but lacks chitinolytic activity. CHI3L1 has shown better performance in diagnosing liver fibrosis than other noninvasive methods in chronic hepatitis B patients.

Scientists specializing in Hepatology at the University of Chinese Academy of Sciences (Ningbo, China) enrolled in a retrospective study the following: matched age and gender subjects, 40 patients with liver cirrhosis, 40 patients with chronic hepatitis, and 40 healthy subjects were enrolled in the control group. The data was collected from December 2018 to April 2020. The serum CHI3L1 level was determined by enzyme-linked immunosorbent assay (ELISA) and in a blinded manner.

The CHI3L1 ELISA Kit was produced by Proprium Biotech Company Limited, (Hangzhou, China). The expression level of CHI3L1 was detected once the subjects first visit the clinic or admit to hospital. The follow-up time was 8 to 22 months. During the follow-up period, laboratory monitoring was performed every 3 to 6 months, including routine blood chemistry tests and imaging studies using computed tomography (CT) or magnetic resonance imaging (MRI) to monitor disease status. The clinicopathological data of 50 paired HCC and adjacent non-tumor tissues as well as 278 unpaired HCC tissues, and the relative expression levels of CHI3L1 was studied.

The investigators reported that the median serum level of CHI3L1 in the HCC group was 168.84 ng/mL (95%CI = 96.24, 322.61 ng/mL), which was significantly higher than the median serum level of CHI3L1 in the control group, median = 71.36 ng/mL (95% CI = 48.63, 114.77 ng/mL). Serum CHI3L1 level was closely correlated with serum α-fetoprotein (AFP) level, tumor-node-metastasis (TNM) stage, Child-Pugh stage, the maximum diameter of tumor, and presence of liver cirrhosis, but there was no significant correlation between gender and age.

The patients with high AFP level (>400 ng/L), TNM III + IV stage, large tumor diameter, liver cirrhosis, and Child-Pugh B + C had higher serum CHI3L1 levels. The overall survival (OS) rate of patients with high expression of CHI3L1 was significantly lower than that of patients with low expression of CHI3L1. Combining the serum CHI3L1 and α-fetoprotein (AFP) by a binary logistic regression model can increase the diagnostic sensitivity to 97.5%. Multivariate Cox regression analysis indicated that CHI3L1 is an independent prognostic factor in patients with HCC.

The authors concluded that they compared the difference of serum CHI3L1 between the HCC group and the control group, analyzed the diagnostic performance of CHI3L1 for HCC, and evaluated the prognostic power of serum CHI3L1 in HCC patients. The results showed that serum CHI3L1 can help to increase diagnostic power and evaluate prognosis for HCC patients. The study was published on January 16, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
University of Chinese Academy of Sciences
Proprium Biotech Company Limited


New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.